Optical coherence tomography angiography findings in patients with branch retinal
            vein occlusion treated with Anti-VEGF

Çiloğlu, Emine; Doğan, Neşe Çetin

doi:10.5935/0004-2749.20200017

“…By using OCTA, Suzuki et al reported an improvement in the nonperfused areas after anti-VEGF therapy, with more frequent injections resulting in a greater reduction in ischemic areas [17]. Similarly, Ciloglu et al found a significant increase in parafoveal VD values after anti-VEGF treatment [42]. We found no changes in VD and VLD with anti-VEGF treatment over the follow-up period, in accordance with previous reports [18,43].…”

Section: Discussionsupporting

confidence: 91%

Longitudinal Changes on Optical Coherence Tomography Angiography in Retinal Vein Occlusion

Tripathy

¹

,

Le

²

,

Cicinelli

³

et al. 2021

JCM

View full text Add to dashboard Cite

Background: To evaluate the longitudinal changes on optical coherence tomography angiography (OCTA) in retinal vein occlusion (RVO). Methods: Retrospective study of patients with RVO treated with intravitreal anti-vascular endothelial growth factors (VEGF) for macular edema. Foveal avascular zone (FAZ) area, vessel density (VD), vessel length density (VLD), and adjusted flow index (AFI) were calculated. The unaffected eye of each participant was used as a control. Results: Twelve RVO eyes were included, receiving 6 ± 3 anti-VEGF injections over a follow-up of 10.4 ± 3.1 months. Compared to fellow eyes, RVO eyes had lower VD and VLD at inclusion (p = 0.07 and p = 0.04) and last visit (p = 0.002 and p < 0.001). VD, AFI, and VLD did not change over time, while FAZ area increased in RVO eyes (+0.016 ± 0.024 mm2, p = 0.04). AFI correlated with duration of disease (r = 0.63, p = 0.02). Visual acuity was inversely related to VD and VLD over the follow-up. Conclusions: OCTA parameters remained stable with sustained anti-VEGF treatment in RVO, while changes in the FAZ area may suggest capillary remodeling after RVO.

show abstract

“…Different effects of anti-VEGF drugs on retinal vascular density in patients with RVO have been reported recently. Some studies have shown that macular vascular density increases after anti-VEGF treatment in RVO [11,18,19].…”

Section: Discussionmentioning

confidence: 99%

“…Different effects of anti-VEGF drugs on retinal vascular density in patients with RVO have been reported recently. Some studies have shown that macular vascular density increases after anti-VEGF treatment in RVO [ 11 , 18 , 19 ]. This may be due to the decrease in VD caused by acute macular edema, which can be improved with reduced macular edema after anti-VEGF treatment [ 11 , 18 ].…”

Section: Discussionmentioning

confidence: 99%

“…Some studies have shown that macular vascular density increases after anti-VEGF treatment in RVO [ 11 , 18 , 19 ]. This may be due to the decrease in VD caused by acute macular edema, which can be improved with reduced macular edema after anti-VEGF treatment [ 11 , 18 ]. Other authors suggested that anti-VEGF drugs stimulated the production of NO to cause vasodilation, which results in an increase in VD [ 19 ].…”

Section: Discussionmentioning

confidence: 99%

“…e retinal vascular density (VD) and the foveal avascular zone (FAZ) of the macular fovea are measured quantitatively for different layers [7,8]. Several studies have indicated that OCTA can be used to evaluate microvascular changes in patients with BRVO before and after anti-VEGF treatment and as a valuable imaging tool for the follow-up evaluation in BRVO eyes [7][8][9][10][11]. However, a few studies have reported the correlation of anatomy and visional function in BRVO eyes evaluated with OCTA.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Changes in Macular Microvascular Structure in Macular Edema Secondary to Branch Retinal Vein Occlusion Treated with Antivascular Endothelial Growth Factor for One Year

Song

¹

,

Yu

²

,

Zhang

³

et al. 2021

Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose. To observe the changes in macular microvascular structure and the correlation between anatomy and visual function in patients with macular edema secondary to branch retinal vein occlusion (BRVO) treated with antivascular endothelial growth factor for one year. Methods. This prospective study enrolled 39 patients (one eye per patient) who received intravitreal injections of ranibizumab for macular edema secondary to BRVO. All patients received a minimum of 3 initial monthly ranibizumab injections and criteria-driven pro re nata (PRN) dosing thereafter for visual acuity (VA) and central retinal thickness (CRT) stabilization. The follow-up period of this study was one year. The vascular density (VD) of the superficial retinal capillary plexus (SCP) and deep retinal capillary plexus (DCP), the foveal avascular zone (FAZ) area, the FAZ perimeter, the VD within a 300 μm wide ring surrounding the FAZ (FD-300), and the acircularity index (AI) were measured automatically by optical coherence tomography angiography (OCTA) at baseline, month 6, and month 12. Results. Compared with those before treatment, the VD of the SCP significantly decreased 6 months after treatment ( P < 0.05 ), while the area and perimeter of the FAZ increased significantly ( P < 0.01 ). After 12 months of treatment, the area and perimeter of the FAZ increased significantly ( P < 0.01 ). There was no significant difference in any parameters between 12 months and 6 months after treatment ( P > 0.05 ). The change in BCVA was negatively correlated with the VD of the SCP at 12 months ( P = 0.0447 , r = −0.3233). There was a relationship between the DBP and AI, and CRT was related to VD of DCP at baseline ( P = 0.028 , 0.0209 ; r = 0.383, −0.384). The PERIM and AI at 12 months were significantly associated with the recurrence of macular edema, and the changes in vascular density in the SCP and PERIM were significantly associated with the number of injections within 12 months ( P < 0.05 ). Conclusions. One year after ranibizumab treatment, the area and perimeter of the FAZ were enlarged, while the VD of the SCP and DCP remained stable, which indicated that ranibizumab treatment did not improve macular blood supply and macular ischemia in BRVO patients.

show abstract

Macular Vessel Density Analysis Using Optical Coherence Tomography Angiography before and after Intravitreal Bevacizumab Injection in Branch Retinal Vein Occlusion

Jun

¹

,

Seo

²

,

Moon

³

2023

J Retin

0

View full text Add to dashboard Cite

Optical coherence tomography angiography findings in patients with branch retinal vein occlusion treated with Anti-VEGF

Cited by 4 publications

References 0 publications

Longitudinal Changes on Optical Coherence Tomography Angiography in Retinal Vein Occlusion

Longitudinal Changes on Optical Coherence Tomography Angiography in Retinal Vein Occlusion

Changes in Macular Microvascular Structure in Macular Edema Secondary to Branch Retinal Vein Occlusion Treated with Antivascular Endothelial Growth Factor for One Year

Macular Vessel Density Analysis Using Optical Coherence Tomography Angiography before and after Intravitreal Bevacizumab Injection in Branch Retinal Vein Occlusion

Contact Info

Product

Resources

About